MOLN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.280

-6.67%

0.000

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Molecular Partners AG (MOLN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.49%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+15.49%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 4.325

Low

4.00

Averages

8.33

High

12.00

Current: 4.325

Low

4.00

Averages

8.33

High

12.00

JPMorgan

Richard Vosser

Neutral

downgrade

2025-12-08

Reason

JPMorgan

Richard Vosser

Price Target

2025-12-08

downgrade

Neutral

Reason

JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $3.75 from $4 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.

JPMorgan

Neutral

downgrade

2025-12-08

Reason

JPMorgan

Price Target

2025-12-08

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Molecular Partners to CHF 3 from CHF 3.50 and keeps a Neutral rating on the shares.

JPMorgan

Richard Vosser

Neutral

downgrade

2025-09-03

Reason

JPMorgan

Richard Vosser

Price Target

2025-09-03

downgrade

Neutral

Reason

JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $4 from $4.50 and keeps a Neutral rating on the shares.

Valuation Metrics

The current forward P/E ratio for Molecular Partners AG (MOLN.O) is -3.22, compared to its 5-year average forward P/E of -2.91. For a more detailed relative valuation and DCF analysis to assess Molecular Partners AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.91

Current PE

-3.22

Overvalued PE

2.06

Undervalued PE

-7.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.44

Current EV/EBITDA

-0.74

Overvalued EV/EBITDA

34.23

Undervalued EV/EBITDA

-29.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29.18

Current PS

0.00

Overvalued PS

71.95

Undervalued PS

-13.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MOLN News & Events

Events Timeline

No data

News

3.5

12-11Globenewswire

Molecular Partners Forms Scientific Advisory Board to Advance Radiopharmaceutical Development

3.5

12-11Newsfilter

Molecular Partners Forms Scientific Advisory Board to Advance Radiopharmaceutical Development

9.0

12-07Globenewswire

Molecular Partners Presents Initial MP0533 Trial Data, 8 Patients Achieve Response

People Also Watch

Frequently Asked Questions

What is Molecular Partners AG (MOLN) stock price today?

The current price of MOLN is 4.325 USD — it has increased 0 % in the last trading day.

What is Molecular Partners AG (MOLN)'s business?

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

What is the price predicton of MOLN Stock?

What is Molecular Partners AG (MOLN)'s revenue for the last quarter?

Molecular Partners AG revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Molecular Partners AG (MOLN)'s earnings per share (EPS) for the last quarter?

Molecular Partners AG. EPS for the last quarter amounts to -0.33 USD, decreased -32.65 % YoY.

What changes have occurred in the market's expectations for Molecular Partners AG (MOLN)'s fundamentals?

How many employees does Molecular Partners AG (MOLN). have?

Molecular Partners AG (MOLN) has 159 emplpoyees as of December 15 2025.

What is Molecular Partners AG (MOLN) market cap?

Today MOLN has the market capitalization of 161.75M USD.